Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk
C Leibler, A Thiolat, C Hénique… - Journal of the …, 2018 - journals.lww.com
Generation of de novo donor-specific antibodies (dnDSAs) after renal transplant is
recognized as the leading cause of late transplant failure. Hence, the optimal
immunosuppressive strategies to limit dnDSA development need to be defined. Recent
clinical trials using the novel costimulatory blockade agent CTLA4-Ig (Belatacept) have
shown that kidney transplant recipients (KTRs) treated with Belatacept have better graft
survival and function and a lower proportion of dnDSAs than control-treated KTRs …
recognized as the leading cause of late transplant failure. Hence, the optimal
immunosuppressive strategies to limit dnDSA development need to be defined. Recent
clinical trials using the novel costimulatory blockade agent CTLA4-Ig (Belatacept) have
shown that kidney transplant recipients (KTRs) treated with Belatacept have better graft
survival and function and a lower proportion of dnDSAs than control-treated KTRs …
